Background: Bacillus Calmette-Guerin (BCG) is the standard of care for adjuvant intravesical instillation therapy for intermediate- and high-risk non-muscle invasive bladder cancer (NMIBC) after complete transurethral resection. Increasing evidence suggests that there are marked differences in outcomes according to BCG substrains. BCG-Moreau was recently introduced to the European market to cover the issue of BCG shortage, but there are little data regarding the oncologic efficacy. Methods: We retrospectively analyzed 295 consecutive patients, who received adjuvant intravesical instillation therapy with BCG-Moreau for intermediate- and high-risk NMIBC between October 2007 and April 2013 at a single institution. The end points of this study were time to first recurrence and progression to muscle-invasive disease. Results: Median age was 66 years (interquartile range 59-74, mean 65.9 years). According to the EAU risk group, 76 patients presented with intermediate-risk and 219 patients with high-risk NMIBC. The 5-year recurrence-free survival and progression-free survival rate was 64.8% (95% CI 52.8-74.4) and 81.4% (95% CI 65.2-90.2), respectively. Conclusions: BCG-Moreau is an effective substrain for adjuvant instillation therapies of NMIBC, and outcomes appear to be comparable to series using other substrains. During worldwide shortage of BCG-TICE, Connaught and RIVM, BCG-Moreau may serve as an equally effective alternative.

Keywords:
Bacillus Calmette-Guerin, Moreau-strain, Recurrence, Progression, Onco BCG
1.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-E386.
2.
World Health Organization: Fact Sheets by Cancer. 2012 (cited February 11, 2015).
3.
Martin-Doyle W, Leow JJ, Orsola A, Chang SL, Bellmunt J: Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients. J Clin Oncol 2015;33:643-650.
4.
Gontero P, Sylvester R, Pisano F, Joniau S, Vander Eeckt K, Serretta V, et al: Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients. Eur Urol 2015;67:74-82.
5.
Gontero P, Gillo A, Fiorito C, Oderda M, Pacchioni D, Casetta G, et al: Prognostic factors of ‘high-grade' Ta bladder cancers according to the WHO 2004 classification: are these equivalent to ‘high-risk' non-muscle-invasive bladder cancer? Urol Int 2014;92:136-142.
6.
Shariat SF, Chade DC, Karakiewicz PI, Scherr DS, Dalbagni G: Update on intravesical agents for non-muscle-invasive bladder cancer. Immunotherapy 2010;2:381-392.
7.
Chade DC, Shariat SF, Dalbagni G: Intravesical therapy for urothelial carcinoma of the urinary bladder: a critical review. Int Braz J Urol 2009;35:640-650; discussion 651.
8.
Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, et al: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 2013;64:639-653.
9.
Gontero P, Bohle A, Malmstrom PU, O'Donnell MA, Oderda M, Sylvester R, et al: The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer. Eur Urol 2010;57:410-429.
10.
Herr HW, Dalbagni G, Donat SM: Bacillus Calmette-Guérin without maintenance therapy for high-risk non-muscle-invasive bladder cancer. Eur Urol 2011;60:32-36.
11.
Swietek N, Waldert M, Rom M, Schatzl G, Wiener HG, Susani M, et al: The value of transurethral bladder biopsy after intravesical bacillus Calmette-Guérin instillation therapy for nonmuscle invasive bladder cancer: a retrospective, single center study and cumulative analysis of the literature. J Urol 2012;188:748-753.
12.
Xylinas E, Kent M, Kluth L, Pycha A, Comploj E, Svatek RS, et al: Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. Br J Cancer 2013;109:1460-1466.
13.
Soukup V, Dušková J, Pešl M, Čapoun O, Feherová Z, Zámečník L, et al: The prognostic value of T1 bladder cancer substaging: a single institution retrospective study. Urol Int 2014;92:150-156.
14.
Herr HW, Morales A: History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J Urol 2008;179:53-56.
15.
Gan C, Mostafid H, Khan MS, Lewis DJ: BCG immunotherapy for bladder cancer - the effects of substrain differences. Nat Rev Urol 2013;10:580-588.
16.
Rentsch CA, Birkhäuser FD, Biot C, Gsponer JR, Bisiaux A, Wetterauer C, et al: Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. Eur Urol 2014;66:677-688.
17.
Site CP: Mold at Toronto plant may affect supplies of cancer drug. http://www.cbc.ca/news/canada/toronto/mould-at-toronto-plant-may-affect-supplies-of-cancer-drug-1.1282152 (cited April 4, 2015).
18.
Mostafid AH, Palou Redorta J, Sylvester R, Witjes JA: Therapeutic options in high-risk non-muscle-invasive bladder cancer during the current worldwide shortage of Bacille Calmette-Guérin. Eur Urol 2015;67:359-360.
19.
US Food and Drug Administration: CBER-Regulated Products: Current Shortages. http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/Shortages/ucm351921.htm (cited August 17, 2015).
20.
Medac GmbH: Newsticker. 2015. http://www.medac.de/news/detail/news/detail/News/newsticker (cited August 17, 2015).
21.
Farah NB, Ghanem R, Amr M: Treatment efficacy and tolerability of intravesical Bacillus Calmette-Guerin (BCG)-RIVM strain: induction and maintenance protocol in high grade and recurrent low grade non-muscle invasive bladder cancer (NMIBC). BMC Urol 2014;14:11.
22.
Oddens J, Brausi M, Sylvester R, Bono A, van de Beek C, van Andel G, et al: Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 2013;63:462-472.
23.
Fonseca FP, Bachega W Jr, Zequi SC, Sarkis AS, Guimaraes G, Priante AV, et al: Treatment of patients with superficial bladder cancer stratified by risk groups treated with lyophilized Moreau-Rio de Janeiro BCG strain. Int Braz J Urol 2002;28:426-435; discussion 435-436.
24.
Secanella-Fandos S, Luquin M, Julián E: Connaught and Russian strains showed the highest direct antitumor effects of different Bacillus Calmette-Guérin substrains. J Urol 2013;189:711-718.
25.
Hemdan T, Johansson R, Jahnson S, Hellström P, Tasdemir I, Malmström PU: 5-year outcome of a randomized prospective study comparing bacillus Calmette-Guérin with epirubicin and interferon-α2b in patients with T1 bladder cancer. J Urol 2014;191:1244-1249.
26.
Alkhateeb SS, Van Rhijn BW, Finelli A, van der Kwast T, Evans A, Hanna S, et al: Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors. J Urol 2010;184:81-86.
27.
Martínez-Piñeiro L, Portillo JA, Fernández JM, Zabala JA, Cadierno I, Moyano JL, et al: Maintenance therapy with 3-monthly Bacillus Calmette-Guérin for 3 years is not superior to standard induction therapy in high-risk non-muscle-invasive urothelial bladder carcinoma: final results of randomised CUETO study 98013. Eur Urol 2015;68:256-262.
28.
Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et al: Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000;163:1124-1129.
29.
Yoo KH, Lim TJ, Chang SG: Monthly intravesical bacillus Calmette-Guérin maintenance therapy for non-muscle-invasive bladder cancer: 10-year experience in a single institute. Exp Ther Med 2012;3:221-225.
30.
Noon AP, Kulkarni GS: All bacillus Calmette-Guérin (BCG) strains are equal, but some BCG strains are more equal than others. Eur Urol 2014;66:689-691.
31.
Rink M, Xylinas E, Babjuk M, Pycha A, Karakiewicz PI, Novara G, et al: Smoking reduces the efficacy of intravesical bacillus Calmette-Guérin immunotherapy in non-muscle-invasive bladder cancer. Eur Urol 2012;62:1204-1206.
32.
Sfakianos JP, Shariat SF, Favaretto RL, Rioja J, Herr HW: Impact of smoking on outcomes after intravesical bacillus Calmette-Guérin therapy for urothelial carcinoma not invading muscle of the bladder. BJU Int 2011;108:526-530.
33.
Zlotta AR, van Vooren JP, Huygen K, Drowart A, Decock M, Pirson M, et al: What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary? Eur Urol 2000;37:470-477.
34.
Sylvester RJ, Oosterlinck W, Witjes JA: The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol 2008;53:709-719.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.